Director Thomas G. Wiggans filed a Form 4 with the SEC on November 17, 2026, disclosing the cancellation of a stock option in connection with the consummation of the merger between Pacira BioSciences, Inc. and a subsidiary of Viatris Inc.
Key Highlights
- Reporting person: Thomas G. Wiggans, identified as a Director of Pacira BioSciences, Inc.
- Transaction date: November 17, 2026, the effective time of the merger.
- Option canceled: A stock option (right to buy) covering 32,675 shares of common stock with an exercise price of $23.42 per share was disposed of (transaction code D).
- Resulting ownership: Following the transaction, Wiggans held 0 derivative securities of this type.
- Merger terms: The Offer Price was $36.50 per share, net of applicable withholding taxes and without interest, according to the filing.
- Post-merger structure: According to the filing, Pacira BioSciences continued as the surviving corporation and became a wholly owned subsidiary of Viatris.
Wiggans Option Disposal at Pacira BioSciences Merger Effective Time
According to the Form 4 filed on November 17, 2026, Thomas G. Wiggans, a Director of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the cancellation of a stock option as a direct result of the closing of a merger transaction. The filing identifies the relevant agreement as the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc. as Purchaser.
The filing states that at the effective time of the merger on November 17, 2026, Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira continuing as the surviving corporation and becoming a wholly owned subsidiary of Viatris. The filing further discloses that each outstanding option to purchase shares, whether vested or unvested, was canceled and converted into the right to receive a cash amount equal to the product of the total number of shares subject to the option multiplied by the excess, if any, of the $36.50 Offer Price over the per-share exercise price, subject to applicable tax withholdings.
In the case of Wiggans, the canceled option covered 32,675 shares at an exercise price of $23.42 per share, with an expiration date of June 10, 2036. Because the $23.42 exercise price was below the $36.50 Offer Price, the option carried a positive spread. The filing also states that any option with a per-share exercise price greater than or equal to the Offer Price was canceled at the effective time with no consideration payable. Following the reported transaction, Wiggans's beneficially owned derivative securities of this type are listed as 0. The Form 4 was signed by Kristen Williams as Attorney-in-Fact on November 17, 2026.
What Was Disclosed
Wiggans disclosed the cancellation of one stock option covering 32,675 shares at an exercise price of $23.42, with no derivative securities of this type remaining, as a result of the November 17, 2026 effective time of the Pacira BioSciences and Viatris merger.




Please wait processing your request...